Journal of Diabetes Science and Technology最新文献_第10页

HIT4HYPOS Continuous Glucose Monitoring Data Analysis: The Effects of High-Intensity Interval Training on Hypoglycemia in People With Type 1 Diabetes and Impaired Awareness of Hypoglycemia. HIT4HYPOS 连续血糖监测数据分析：高强度间歇训练对 1 型糖尿病患者和低血糖意识受损者低血糖的影响。

IF 4.1

Journal of Diabetes Science and Technology Pub Date : 2024-09-23 DOI: 10.1177/19322968241273845

Catriona M Farrell, Giacomo Cappon, Daniel J West, Andrea Facchinetti, Rory J McCrimmon

{"title":"HIT4HYPOS Continuous Glucose Monitoring Data Analysis: The Effects of High-Intensity Interval Training on Hypoglycemia in People With Type 1 Diabetes and Impaired Awareness of Hypoglycemia.","authors":"Catriona M Farrell, Giacomo Cappon, Daniel J West, Andrea Facchinetti, Rory J McCrimmon","doi":"10.1177/19322968241273845","DOIUrl":"10.1177/19322968241273845","url":null,"abstract":"Aims: To assess the impact of high-intensity interval training (HIIT) on hypoglycemia frequency and duration in people with type 1 diabetes (T1D) with impaired awareness of hypoglycemia (IAH).Methods: Post hoc analysis of four weeks of continuous glucose monitoring (CGM) data from HIT4HYPOS; a parallel-group study comparing HIIT + CGM versus no exercise + CGM in 18 participants with T1D and IAH.Results: When compared with those participating individuals not exercising, HIIT did not increase total hypoglycemia frequency, THypo(L1) 1.44 [1.00-2.77]% versus 2.53 [1.46-4.23]%; P = .335, THypo(L2) 0.25 [0.09-0.37]% versus 0.45 [0.20-0.78]%; P = .146, HIIT + CGM versus CGM, respectively, rate (EventPerWeekHypo 5.30 [3.35-8.27] #/week vs 7.45 [3.54-10.81] #/week, P = .340) or duration (DurationHypo 33.33 [27.60-39.10] minutes vs 39.56 [31.00-48.38] minutes; P = .219, HIIT + CGM vs CGM, respectively). There was a reduction in nocturnal hypoglycemia in those who carried out HIIT, THypo(L1) 0.50 [0.13-0.97]% versus 2.45 [0.77-4.74]%; P = .076; THypo(L2) 0.00 [0.00-0.03]% versus 0.49 [0.13-0.74]%; P = .006, HIIT + CGM versus CGM, respectively.Conclusions/interpretation: Based on CGM data collected from a real-world study of four weeks of HIIT versus no exercise in individuals with T1D and IAH, we conclude that HIIT does not increase hypoglycemia, and in fact reduces exposure to nocturnal hypoglycemia.","PeriodicalId":15475,"journal":{"name":"Journal of Diabetes Science and Technology","volume":" ","pages":"19322968241273845"},"PeriodicalIF":4.1,"publicationDate":"2024-09-23","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11571604/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142288370","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Prediction of People With Type 2 Diabetes Not Achieving HbA1c Target After Initiation of Fast-Acting Insulin Therapy: Using Machine Learning Framework on Clinical Trial Data. 预测 2 型糖尿病患者在接受速效胰岛素治疗后 HbA1c 达不到目标值的情况：在临床试验数据中使用机器学习框架。

IF 4.1

Journal of Diabetes Science and Technology Pub Date : 2024-09-20 DOI: 10.1177/19322968241280096

Carsten Wridt Stoltenberg, Stine Hangaard, Ole Hejlesen, Thomas Kronborg, Peter Vestergaard, Morten Hasselstrøm Jensen

{"title":"Prediction of People With Type 2 Diabetes Not Achieving HbA1c Target After Initiation of Fast-Acting Insulin Therapy: Using Machine Learning Framework on Clinical Trial Data.","authors":"Carsten Wridt Stoltenberg, Stine Hangaard, Ole Hejlesen, Thomas Kronborg, Peter Vestergaard, Morten Hasselstrøm Jensen","doi":"10.1177/19322968241280096","DOIUrl":"10.1177/19322968241280096","url":null,"abstract":"Background and aims: Glycemic control is crucial for people with type 2 diabetes. However, only about half achieve the advocated HbA1c target of ≤7%. Identifying those who will probably struggle to reach this target may be valuable as they require additional support. Thus, the aim of this study was to develop a model to predict people with type 2 diabetes not achieving HbA1c target after initiating fast-acting insulin.Methods: Data from a randomized controlled trial (NCT01819129) of participants with type 2 diabetes initiating fast-acting insulin were used. Data included demographics, clinical laboratory values, self-monitored blood glucose (SMBG), health-related quality of life (SF-36), and body measurements. A logistic regression was developed to predict HbA1c target nonachievers. A potential of 196 features was input for a forward feature selection. To assess the performance, a 20-repeated stratified 5-fold cross-validation with area under the receiver operating characteristics curve (AUROC) was used.Results: Out of the 467 included participants, 98 (21%) did not achieve HbA1c target of ≤7%. The forward selection identified 7 features: baseline HbA1c (%), mean postprandial SMBG at all meals 3 consecutive days before baseline (mmol/L), sex, no ketones in urine, baseline albumin (g/dL), baseline low-density lipoprotein cholesterol (mmol/L), and traces of protein in urine. The model had an AUROC of 0.745 [95% CI = 0.734, 0.756].Conclusions: The model was able to predict those who did not achieve HbA1c target with promising performance, potentially enabling early identification of people with type 2 diabetes who require additional support to reach glycemic control.","PeriodicalId":15475,"journal":{"name":"Journal of Diabetes Science and Technology","volume":" ","pages":"19322968241280096"},"PeriodicalIF":4.1,"publicationDate":"2024-09-20","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11571615/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142288371","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Diabetic Peripheral Neuropathy: Emerging Treatments of Neuropathic Pain and Novel Diagnostic Methods. 糖尿病周围神经病变：新出现的神经病理性疼痛治疗方法和新型诊断方法。

IF 4.1

Journal of Diabetes Science and Technology Pub Date : 2024-09-16 DOI: 10.1177/19322968241279553

Johan Røikjer, Mette Krabsmark Borbjerg, Trine Andresen, Rocco Giordano, Claus Vinter Bødker Hviid, Carsten Dahl Mørch, Pall Karlsson, David C Klonoff, Lars Arendt-Nielsen, Niels Ejskjaer

{"title":"Diabetic Peripheral Neuropathy: Emerging Treatments of Neuropathic Pain and Novel Diagnostic Methods.","authors":"Johan Røikjer, Mette Krabsmark Borbjerg, Trine Andresen, Rocco Giordano, Claus Vinter Bødker Hviid, Carsten Dahl Mørch, Pall Karlsson, David C Klonoff, Lars Arendt-Nielsen, Niels Ejskjaer","doi":"10.1177/19322968241279553","DOIUrl":"10.1177/19322968241279553","url":null,"abstract":"Background: Diabetic peripheral neuropathy (DPN) is a prevalent and debilitating complication of diabetes, often leading to severe neuropathic pain. Although other diabetes-related complications have witnessed a surge of emerging treatments in recent years, DPN has seen minimal progression. This stagnation stems from various factors, including insensitive diagnostic methods and inadequate treatment options for neuropathic pain.Methods: In this comprehensive review, we highlight promising novel diagnostic techniques for assessing DPN, elucidating their development, strengths, and limitations, and assessing their potential as future reliable clinical biomarkers and endpoints. In addition, we delve into the most promising emerging pharmacological and mechanistic treatments for managing neuropathic pain, an area currently characterized by inadequate pain relief and a notable burden of side effects.Results: Skin biopsies, corneal confocal microscopy, transcutaneous electrical stimulation, blood-derived biomarkers, and multi-omics emerge as some of the most promising new techniques, while low-dose naltrexone, selective sodium-channel blockers, calcitonin gene-related peptide antibodies, and angiotensin type 2 receptor antagonists emerge as some of the most promising new drug candidates.Conclusion: Our review concludes that although several promising diagnostic modalities and emerging treatments exist, an ongoing need persists for the further development of sensitive diagnostic tools and mechanism-based, personalized treatment approaches.","PeriodicalId":15475,"journal":{"name":"Journal of Diabetes Science and Technology","volume":" ","pages":"19322968241279553"},"PeriodicalIF":4.1,"publicationDate":"2024-09-16","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11571639/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142288366","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Batteries Within Diabetes Devices: A Narrative Review on Recycling, Environmental, and Sustainability Perspective. 糖尿病设备中的电池：从回收、环境和可持续性角度的叙述性评论。

IF 4.1

Journal of Diabetes Science and Technology Pub Date : 2024-09-10 DOI: 10.1177/19322968241278374

Parizad Avari, Yi Cai, Vivek Verma, Monika Reddy, Madhavi Srinivasan, Nick Oliver

引用次数: 0

Electronic Health Record Alert With Heart Failure Risk and Sodium Glucose Cotransporter 2 Inhibitor Prescriptions in Diabetes: A Randomized Clinical Trial. 糖尿病患者心衰风险和葡萄糖钠转运体 2 抑制剂处方的电子健康记录提示：随机临床试验。

IF 4.1

Journal of Diabetes Science and Technology Pub Date : 2024-09-10 DOI: 10.1177/19322968241264747

Matthew W Segar, Kershaw V Patel, Neil Keshvani, Vaishnavi Kannan, Duwayne Willett, David C Klonoff, Ambarish Pandey

{"title":"Electronic Health Record Alert With Heart Failure Risk and Sodium Glucose Cotransporter 2 Inhibitor Prescriptions in Diabetes: A Randomized Clinical Trial.","authors":"Matthew W Segar, Kershaw V Patel, Neil Keshvani, Vaishnavi Kannan, Duwayne Willett, David C Klonoff, Ambarish Pandey","doi":"10.1177/19322968241264747","DOIUrl":"10.1177/19322968241264747","url":null,"abstract":"Background: Sodium glucose cotransporter 2 inhibitors (SGLT2i) prevent heart failure (HF) in patients with type 2 diabetes mellitus (T2DM) but prescription rates are low. The effect of an electronic health record (EHR) alert notifying providers of patients' estimated risk of developing HF on SGTL2i prescriptions is unknown.Methods: This was a pragmatic, randomized clinical trial that compared an EHR alert and usual care among patients with T2DM and no history of HF or SGLT2i use at a single center. The EHR alert notified providers of their patient's HF risk and recommended HF prevention strategies. Randomization was performed at the provider level across general and subspecialty internal medicine as well as family medicine outpatient clinics. The primary outcome was proportion of SGLT2i prescriptions within 30 days. Proportion of natriuretic peptide (NP) tests within 90 days was also assessed.Results: A total of 1524 patients (median age 75 years, 45% women, 23% Black) were enrolled between September 28, 2021, and April 29, 2022 from 189 outpatient clinics. SGLT2i were prescribed to 1.2% (9/780) of patients in the EHR alert group and 0% (0/744) of those in the usual care group (P value = 0.009). Natriuretic peptide testing was performed within 90 days among 10.8% (84/780) of patients in the EHR alert group and 7.3% (54/744) of patients in the usual care group (P value = 0.02).Conclusions: In a single-center trial with low overall SGLT2i use, an EHR alert incorporating HF risk information significantly increased SGLT2i prescriptions and NP testing although the absolute rates were low.","PeriodicalId":15475,"journal":{"name":"Journal of Diabetes Science and Technology","volume":" ","pages":"19322968241264747"},"PeriodicalIF":4.1,"publicationDate":"2024-09-10","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11571329/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142288367","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

FDA Interoperability Designation-Creating Options for People With Diabetes and Pump Companies: Regulatory, Technological, and Commercial Perspectives. FDA 互操作性指定--为糖尿病患者和泵公司创造选择：监管、技术和商业视角。

IF 4.1

Journal of Diabetes Science and Technology Pub Date : 2024-09-10 DOI: 10.1177/19322968241271304

David C Klonoff, Cindy N Ho, Alessandra Ayers, Aiman Abdel-Malek

引用次数: 0

Regarding Singh et al, "Effects, Safety, and Treatment Experience of Advanced Hybrid Closed-Loop Systems in Clinical Practice Among Adults Living With Type 1 Diabetes". 关于 Singh 等人，"先进的混合闭环系统在 1 型糖尿病成人临床实践中的效果、安全性和治疗经验"。

IF 4.1

Journal of Diabetes Science and Technology Pub Date : 2024-09-01 Epub Date: 2024-05-27 DOI: 10.1177/19322968241257003

Laurel H Messer, John B Welsh, Steph Habif, Jordan E Pinsker, Tomas C Walker

引用次数: 0

Concept and Implementation of a Novel Continuous Glucose Monitoring Solution With Glucose Predictions on Board. 带有葡萄糖预测功能的新型连续葡萄糖监测解决方案的概念与实施。

IF 4.1

Journal of Diabetes Science and Technology Pub Date : 2024-09-01 Epub Date: 2024-08-19 DOI: 10.1177/19322968241269927

Timor Glatzer, Christian Ringemann, Daniel Militz, Wiebke Mueller-Hoffmann

引用次数: 0

All Children Deserve to Be Safe, Mothers Too: Evidence and Rationale Supporting Continuous Glucose Monitoring Use in Gestational Diabetes Within the Medicaid Population. 所有儿童和母亲都应享有安全：支持在医疗补助人群中使用 CGM 治疗妊娠糖尿病的证据和理由。

IF 4.1

Journal of Diabetes Science and Technology Pub Date : 2024-09-01 Epub Date: 2023-03-15 DOI: 10.1177/19322968231161317

Carol J Levy, Rodolfo J Galindo, Christopher G Parkin, Jacob Gillis, Nicholas B Argento

{"title":"All Children Deserve to Be Safe, Mothers Too: Evidence and Rationale Supporting Continuous Glucose Monitoring Use in Gestational Diabetes Within the Medicaid Population.","authors":"Carol J Levy, Rodolfo J Galindo, Christopher G Parkin, Jacob Gillis, Nicholas B Argento","doi":"10.1177/19322968231161317","DOIUrl":"10.1177/19322968231161317","url":null,"abstract":"Gestational diabetes mellitus (GDM) is a common metabolic disease of pregnancy that threatens the health of several million women and their offspring. The highest prevalence of GDM is seen in women of low socioeconomic status. Women with GDM are at increased risk of adverse maternal outcomes, including increased rates of Cesarean section delivery, preeclampsia, perineal tears, and postpartum hemorrhage. However, of even greater concern is the increased risk to the fetus and long-term health of the child due to elevated glycemia during pregnancy. Although the use of continuous glucose monitoring (CGM) has been shown to reduce the incidence of maternal and fetal complications in pregnant women with type 1 diabetes and type 2 diabetes, most state Medicaid programs do not cover CGM for women with GDM. This article reviews current statistics relevant to the incidence and costs of GDM among Medicaid beneficiaries, summarizes key findings from pregnancy studies using CGM, and presents a rationale for expanding and standardizing CGM coverage for GDM within state Medicaid populations.","PeriodicalId":15475,"journal":{"name":"Journal of Diabetes Science and Technology","volume":" ","pages":"1198-1207"},"PeriodicalIF":4.1,"publicationDate":"2024-09-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11418457/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"10210482","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Implementation and Evaluation of an Automated Text Message-Based Diabetes Prevention Program for Adults With Pre-diabetes. 针对糖尿病前期成人的基于自动短信的糖尿病预防计划的实施与评估。

IF 4.1

Journal of Diabetes Science and Technology Pub Date : 2024-09-01 Epub Date: 2023-03-22 DOI: 10.1177/19322968231162601

Sanjay Arora, Chun Nok Lam, Elizabeth Burner, Michael Menchine

{"title":"Implementation and Evaluation of an Automated Text Message-Based Diabetes Prevention Program for Adults With Pre-diabetes.","authors":"Sanjay Arora, Chun Nok Lam, Elizabeth Burner, Michael Menchine","doi":"10.1177/19322968231162601","DOIUrl":"10.1177/19322968231162601","url":null,"abstract":"Background: Despite the efficacy of diabetes prevention programs, only an estimated 5% of people with pre-diabetes actually participate. Mobile health (mHealth) holds promise to engage patients with pre-diabetes into lifestyle modification programs by decreasing the referral burden, centralizing remote enrollment, removing the physical requirement of a brick-and-mortar location, lowering operating costs through automation, and reducing time and transportation barriers.Methods: Non-randomized implementation study enrolling patients with pre-diabetes from a large health care organization. Patients were exposed to a text message-based program combining live human coaching guidance and support with automated scheduled, interactive, data-driven, and on-demand messages. The primary analysis examined predicted weight outcomes at 6 and 12 months. Secondary outcomes included predicted changes in HbA1c and minutes of exercise at 6 and 12 months.Results: Of the 163 participants included in the primary analysis, participants had a mean predicted weight loss of 5.5% at six months (P < .001) and of 4.3% at 12 months (P < .001). We observed a decrease in predicted HbA1c from 6.1 at baseline to 5.8 at 6 and 12 months (P < .001). Activity minutes were statistically similar from a baseline of 155.5 minutes to 146.0 minutes (P = .567) and 142.1 minutes (P = .522) at 6 and 12 months, respectively, for the overall cohort.Conclusions: In this real-world implementation of the myAgileLife Diabetes Prevention Program among patients with pre-diabetes, we observed significant decreases in weight and HbA1c at 6 and 12 months. mHealth may represent an effective and easily scalable potential solution to deliver impactful diabetes prevention curricula to large numbers of patients.","PeriodicalId":15475,"journal":{"name":"Journal of Diabetes Science and Technology","volume":" ","pages":"1139-1145"},"PeriodicalIF":4.1,"publicationDate":"2024-09-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11418517/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"9156090","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0